Skip to main content

ADHD

ADHD

A digital therapeutic intervention delivered through a video game-like interface shows promise in improving attention in children with attention deficit/hyperactivity disorder (ADHD), according to a study in The Lancet…

ADHD
As children diagnosed with attention-deficit/hyperactivity disorder transition into adolescence and young adulthood, primary care providers are missing the mark in monitoring them for several important health risks, a study warns.
ADHD
Purpose: Evening-dosed HLD200 is a delayed-release and extended-release methylphenidate (DR/ER-MPH) designed to provide treatment effect in the early morning, throughout the day, and into the evening. This pivotal, phase 3, forced-dose titration…
ADHD
Purpose: Sleep disturbances are associated with attention-deficit/hyperactivity disorder (ADHD) and methylphenidate (MPH) treatment. We assessed whether sleep-related adverse event (AE) rates are affected by sample and study design features of…
ADHD
Adult attention-deficit/hyperactivity disorder (ADHD) can affect work productivity. This survey examined relationships between oral stimulant medication adherence, work productivity and related indirect costs, and ADHD symptom level among US adults…
ADHD
Adult attention-deficit/hyperactivity disorder (ADHD) is associated with impaired executive function (EF). This post hoc analysis examines relationships between changes in ADHD symptoms and EF, as measured by the ADHD-Rating Scale-IV (ADHD-RS-IV)…
ADHD
Background: SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) being developed as a treatment for attention-deficit/hyperactivity disorder (ADHD). Here we present results of a…
ADHD
Background: SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) being developed as a treatment for pediatric attention-deficit/hyperactivity disorder (ADHD). Here we present…
ADHD
Background: SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) being developed as a treatment for pediatric attention-deficit/hyperactivity disorder (ADHD). Here we present…
ADHD
In adults with attention-deficit/hyperactivity disorder (ADHD), SHP465 mixed amphetamine salts (MAS) extended-release reduced ADHD-Rating Scale-IV total score (ADHD-RS-IV-TS) significantly more than placebo. These post hoc analyses examine SHP465…
Back to Top